Bahrain Licensed Foundayo Six Months After the FDA as Lilly Takes Its Oral GLP-1 Global
Bahrain is small. The move matters as evidence of the global rollout Lilly argued a small-molecule GLP-1 would allow.
CI read
FOP Now Has Three Approved Drugs for About 300 US Patients, Two of Them in 37 Days
Three drugs now divide an ultra-rare disease by mechanism, route and age, and the newest competes on convenience and safety.
J&J Is Using Two Tecvayli Trials to Own Myeloma’s First Relapse Whether or Not Patients Had Darzalex
J&J’s frontline success with Darzalex is manufacturing the monotherapy market for Tecvayli at first myeloma relapse.
Roche Claims Best-in-Class Potential for Sefaxersen Without Disclosing How Much It Cut Proteinuria
Sefaxersen hits the same target as Novartis’s Fabhalta. Roche withheld the one number that would show which drug does more.
A Court Vacated the FDA’s Biologic Classification of MiMedx’s Wound Powder Because Similar Products Were Devices
The court did not rule on what AXIOFILL is. It ruled that FDA had not treated like wound care products alike.
Beacon Succeeded in XLRP Where Biogen and J&J Failed, on an Endpoint Neither of Them Used
QuickCI read/Ophthalmology/Cell & Gene Tx Beacon Succeeded in XLRP Where Biogen and J&J Failed, on an Endpoint Neither of Them Used Athithi Verma· 22 September 2026· 2 min read· Synopulse Beacon Therapeutics said on 21 September 2026 that laru-zova met the FDA-endorsed primary endpoint of VISTA, a 12-month randomised trial in 85 males aged 12 … Read more
Brazil Approved AstraZeneca’s Camizestrant 17 Days After the FDA, Whose Own Advisers Had Voted Against It
Every major regulator has now said yes to a strategy the FDA’s advisers doubted. The constraint is a blood test.
Caplyta Doubled the Mania Response Rate, and Only Dry Mouth and Nausea Cleared J&J’s Side Effect Bar
The efficacy is the headline. The competitive case sits in the side effect line, and it points at AbbVie’s Vraylar.
Merck Moved Every Japanese Keytruda Indication to a One-Minute Injection on a Single Lung Cancer Trial
One exposure trial in lung cancer carried every Japanese indication. The contest is now minutes and millilitres.
Japan Clears Five Products in a Day, Two With a Price Cut Attached
Five approvals, one calendar date, one November pricing round. The two expansions are the ones the system taxes.